Overview
With a focus on improving patient outcomes through evidence-based healing solutions and services, Sanara MedTech Inc. markets and distributes wound and skin care products and is seeking to offer wound care and dermatology virtual consultation services via telemedicine to physicians, hospitals, clinics, and all post-acute care settings. Sanara's products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen® to the surgical markets as well as the following products to the wound care market:
BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution, and HYCOL™ Hydrolyzed Collagen Powder and Gel. The company is constantly seeking long-term strategic partnerships with a focus on products and technologies that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry.
Basic Stats
The share price of Sanara MedTech Inc. as of September 5, 2025 is $33.57 / share. This is a decrease of -0.27% from the prior week. The market cap (or net worth) of Sanara MedTech Inc. as of September 5, 2025 is $298.90 MM.
The Factor Analysis chart (below right) shows a view of Sanara MedTech Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 298.90 MM |
| EV | 326.15 MM |
| Shares Out. | 8.90 MM |
| Earnings Date | |
| EPS (TTM) | -1.12 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.42 |
| Short Shares Avail. | 0.15 MM |
| Short Interest | 0.24 MM |
| Short Float | 6.68 % |
| Days to Cover | 9.99 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -4.20 % |
| Volatility (1 yr) | 0.52 |
| Beta | 1.25 |
| Sharpe Ratio (1 yr) | -0.16 |
| Sortino Ratio (1 yr) | -0.30 |
| PE Ratio | -30.08 |
| Price/Book | 8.45 |
| Price/TBV | -32.51 |
| Book/Market | 0.12 |
| EBIT/EV | -0.03 |
| EBIT(3yr avg)/EV | -0.03 |
| ROA | -0.14 |
| ROE | -0.24 |
| ROIC | -0.12 |
| CROIC | 0.13 |
| OCROIC | 0.05 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Sanara MedTech Inc. is $51.00. The forecasts range from a low of $46.46 to a high of $56.70. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Sanara MedTech Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2021-06-30 | Cantor Fitzgerald | Overweight | Initiate | |
| 2023-08-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-11-15 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2023-09-26 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-08-17 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-02-06 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-05-15 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-03-27 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2025-01-23 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-01-23 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-05-15 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-12-23 | HC Wainwright & Co. | Buy | Initiate | |
| 2025-03-26 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-01-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-03-26 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-08-18 | HC Wainwright & Co. | Buy | Buy | Maintains |
